Josep-Maria Ribera

Josep-Maria Ribera publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Josep-Maria Ribera sits on this spectrum.

Josep-Maria Ribera D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Josep-Maria Ribera sits on this spectrum.

Overview

Best Publications

• Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

  Hagop M Kantarjian;Anthony Stein;Nicola Gökbuget;Adele K. Fielding

  1813
  Citations

• Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

  Max S. Topp;Nicola Gökbuget;Anthony S. Stein;Gerhard Zugmaier

  1284
  Citations

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

  María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  620
  Citations

• Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

  Bosch F;López-Guillermo A;Campo E;Ribera Jm

  453
  Citations

• Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

  M. Bruggemann;A. Schrauder;T. Raff;H. Pfeifer

  447
  Citations

• High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

  Joan Bladé;Laura Rosiñol;Ana Sureda;Josep M. Ribera

  440
  Citations

• Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

  Miguel A. Sanz;Pau Montesinos;Chelo Rayón;Alexandra Holowiecka

  412
  Citations

• Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

  A. López-Guillermo;J. Cid;A. Salar;A. López

  403
  Citations

• Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

  Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol

  395
  Citations

• Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  D. Hoelzer;R. Bassan;H. Dombret;A. Fielding

  395
  Citations

• Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

  Josep-María Ribera;Albert Oriol;Miguel-Angel Sanz;Mar Tormo

  337
  Citations

• Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

  Marta Pratcorona;Salut Brunet;Josep Nomdedéu;Josep Maria Ribera

  334
  Citations

• Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

  Albert Oriol;Susana Vives;Jesús-María Hernández-Rivas;Mar Tormo

  312
  Citations

• Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

  Josep-Maria Ribera;Albert Oriol;Mireia Morgades;Pau Montesinos

  305
  Citations

• Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival

  David Valcárcel;Rodrigo Martino;Dolores Caballero;Jesus Martin

  302
  Citations

• Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes

  Francesc Solé;Elisa Luño;Carmen Sanzo;Blanca Espinet

  299
  Citations

• Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

  Philippe Rousselot;Marie Magdelaine Coudé;Nicola Gokbuget;Carlo Gambacorti Passerini

  288
  Citations

• Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial.

  E Cobo;J Cortés;J M Ribera;F Cardellach

  275
  Citations

• Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/ Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

  Anna Sureda;Carme Canals;Reyes Arranz;Dolores Caballero

  261
  Citations

• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

  María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  188
  Citations